Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial
Lingvay, Ildiko, Catarig, Andrei-Mircea, Frias, Juan P, Kumar, Harish, Lausvig, Nanna L, le Roux, Carel W, Thielke, Desirée, Viljoen, Adie, McCrimmon, Rory JJournal:
The Lancet Diabetes & Endocrinology
DOI:
10.1016/S2213-8587(19)30311-0
Date:
September, 2019
File:
PDF, 261 KB
2019
File converter
More search results
More benefits 
